[Preprint] Estudo SOLIDARITY da OMS: Remdesivir, Hidroxicloroquina, Lopinavir e Interferon-β1a não melhoram o prognóstico em pacientes hospitalizados por Covid-19

O Estudo SOLIDARITY da Organização Mundial de Saúde é o maior estudo testando terapêuticas para o Covid-19. Neste estudo randomizado multicêntrico envolvendo 11266 pacientes em 30 países, nenhuma das medicações diminuiu mortalidade ou outros desfechos clínicos relevantes, como necessidade de ventilação mecânica e tempo de internação hospitalar.

Fonte:

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results – medRxiv

Comunicado de imprensa da OMS:

Solidarity Therapeutics Trial produces conclusive evidence on the effectiveness of repurposed drugs for COVID-19 in record time – World Health Organization

Comentário: 

Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – Science

Comentários no Twitter:

Results of the @WHO SOLIDARITY trial:

4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
– hydroxychloroquine
– lopinavir
– remdesevir
– interferon

No clear benefit of any of them on survival. https://t.co/ohtTAFaSnc pic.twitter.com/2fO9E8zs8h

— Martin Landray (@MartinLandray) October 16, 2020

This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint https://t.co/aNGLzLL5uW pic.twitter.com/daOAMVW62u

— Harlan Krumholz (@hmkyale) October 15, 2020